Progyny (PGNY) Stock Forecast, Price Target & Predictions
PGNY Stock Forecast
Progyny stock forecast is as follows: an average price target of $22.67 (represents a 58.09% upside from PGNY’s last price of $14.34) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.
PGNY Price Target
The average price target for Progyny (PGNY) is $22.67 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $36.00 to $18.00. This represents a potential 58.09% upside from PGNY's last price of $14.34.
PGNY Analyst Ratings
According to 10 Wall Street analysts, Progyny's rating consensus is 'Hold'. The analyst rating breakdown for PGNY stock is 0 'Strong Buy' (0.00%), 4 'Buy' (40.00%), 6 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Progyny Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 13, 2024 | Glen Santangelo | Jefferies | $19.00 | $21.61 | -12.08% | 32.50% |
| Nov 13, 2024 | Sarah James | Cantor Fitzgerald | $22.00 | $21.61 | 1.80% | 53.42% |
| Nov 13, 2024 | Jailendra Singh | Truist Financial | $19.00 | $21.61 | -12.08% | 32.50% |
| Sep 20, 2024 | Richard Close | Canaccord Genuity | $18.00 | $16.46 | 9.36% | 25.52% |
| Sep 20, 2024 | Michael Cherny | Bank of America Securities | $22.00 | $16.46 | 33.66% | 53.42% |
| Sep 19, 2024 | Glen Santangelo | Jefferies | $24.00 | $16.55 | 45.01% | 67.36% |
| Sep 19, 2024 | Jailendra Singh | Truist Financial | $33.00 | $17.78 | 85.64% | 130.13% |
| Aug 07, 2024 | Richard Close | Canaccord Genuity | $24.00 | $25.74 | -6.76% | 67.36% |
| Jul 16, 2024 | Constantine Davides | JMP Securities | $36.00 | $29.03 | 24.01% | 151.05% |
| May 17, 2024 | Jailendra Singh | Truist Financial | $37.00 | $27.55 | 34.30% | 158.02% |
| May 10, 2024 | David Larsen | BTIG | $41.00 | $32.50 | 26.15% | 185.91% |
The latest Progyny stock forecast, released on Nov 13, 2024 by Glen Santangelo from Jefferies, set a price target of $19.00, which represents a -12.08% decrease from the stock price at the time of the forecast ($21.61), and a 32.50% increase from PGNY last price ($14.34).
Progyny Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 7 | 11 |
| Avg Price Target | - | $22.43 | $26.82 |
| Last Closing Price | $14.34 | $14.34 | $14.34 |
| Upside/Downside | -100.00% | 56.42% | 87.03% |
In the current month, the average price target of Progyny stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Progyny's last price of $14.34. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 13, 2024 | Jefferies | Buy | Buy | Hold |
| Nov 13, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Sep 20, 2024 | Truist Financial | Market Perform | Market Perform | Hold |
| Sep 20, 2024 | SVB Leerink | Underperform | Underperform | Hold |
| Sep 20, 2024 | Canaccord Genuity | Hold | Hold | Hold |
| Sep 20, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Sep 19, 2024 | Jefferies | Buy | Buy | Hold |
| Sep 19, 2024 | JMP Securities | Underperform | Market Perform | Downgrade |
| Aug 07, 2024 | Raymond James | Market Perform | Market Perform | Hold |
| Aug 07, 2024 | BTIG | Buy | Neutral | Downgrade |
| Aug 07, 2024 | Canaccord Genuity | Reduce | Downgrade | |
| Aug 06, 2024 | Jefferies | Buy | Buy | Hold |
| Jul 16, 2024 | Raymond James | Market Outperform | Market Outperform | Hold |
| Jul 16, 2024 | JMP Securities | Underperform | Underperform | Hold |
| Jul 16, 2024 | JMP Securities | Outperform | Initialise | |
| May 10, 2024 | BTIG | Buy | Buy | Hold |
| May 09, 2024 | KeyBanc | Sector Weight | Downgrade | |
| Dec 19, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
Progyny's last stock rating was published by Jefferies on Nov 13, 2024. The company gave PGNY a "Buy" rating, the same as its previous rate.
Progyny Financial Forecast
Progyny Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $269.94M | $280.89M | $279.37M | $258.39M | $214.32M | $205.37M | $195.00M | $172.22M | $127.55M | $122.28M | $128.65M | $122.13M | $100.30M | $98.93M | $64.61M | $81.02M | $65.12M | $61.20M |
| Avg Forecast | $308.73M | $320.69M | $324.62M | $306.26M | $288.63M | $295.04M | $298.15M | $280.25M | $275.01M | $296.85M | $305.11M | $289.41M | $274.08M | $271.20M | $261.91M | $246.43M | $211.78M | $194.54M | $190.51M | $167.18M | $134.63M | $126.72M | $129.29M | $121.45M | $97.86M | $92.54M | $48.30M | $71.81M | $66.07M | $60.83M |
| High Forecast | $314.42M | $326.60M | $330.60M | $311.90M | $293.95M | $300.47M | $303.65M | $285.41M | $277.23M | $298.99M | $305.21M | $289.41M | $275.88M | $271.20M | $266.73M | $250.97M | $215.68M | $194.54M | $190.51M | $167.18M | $134.63M | $126.72M | $129.29M | $121.45M | $97.86M | $92.54M | $48.30M | $71.81M | $66.07M | $60.83M |
| Low Forecast | $297.90M | $309.44M | $313.23M | $295.51M | $278.50M | $284.68M | $287.69M | $270.42M | $271.81M | $294.72M | $305.00M | $289.41M | $272.09M | $271.20M | $252.72M | $237.79M | $204.35M | $194.54M | $190.51M | $167.18M | $134.63M | $126.72M | $129.29M | $121.45M | $97.86M | $92.54M | $48.30M | $71.81M | $66.07M | $60.83M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 1.04% | 1.07% | 1.05% | 1.01% | 1.06% | 1.02% | 1.03% | 0.95% | 0.97% | 1.00% | 1.01% | 1.02% | 1.07% | 1.34% | 1.13% | 0.99% | 1.01% |
Progyny's average Quarter revenue forecast for Mar 24 based on 3 analysts is $289.41M, with a low forecast of $289.41M, and a high forecast of $289.41M. PGNY's average Quarter revenue forecast represents a 7.21% increase compared to the company's last Quarter revenue of $269.94M (Dec 23).
Progyny EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $13.80M | $18.19M | $15.18M | $15.55M | $3.75M | $11.26M | $9.22M | $306.00K | $1.00K | $9.53M | $12.47M | $12.20M | $1.41M | $5.80M | $-1.35M | $4.84M | $-3.80M | $-7.65M |
| Avg Forecast | $14.77M | $15.35M | $15.53M | $14.66M | $13.81M | $14.12M | $14.27M | $13.41M | $13.16M | $14.21M | $14.60M | $552.33K | $13.12M | $12.98M | $12.53M | $590.73K | $2.94M | $12.39M | $12.13M | $631.80K | $8.57M | $8.07M | $11.50M | $7.73M | $6.23M | $5.89M | $3.08M | $5.33M | $4.21M | $3.87M |
| High Forecast | $15.05M | $15.63M | $15.82M | $14.93M | $14.07M | $14.38M | $14.53M | $13.66M | $13.27M | $14.31M | $14.61M | $662.80K | $13.20M | $12.98M | $12.76M | $708.88K | $3.53M | $12.39M | $12.13M | $758.16K | $8.57M | $8.07M | $13.80M | $7.73M | $6.23M | $5.89M | $3.08M | $6.39M | $4.21M | $3.87M |
| Low Forecast | $14.26M | $14.81M | $14.99M | $14.14M | $13.33M | $13.62M | $13.77M | $12.94M | $13.01M | $14.10M | $14.60M | $441.87K | $13.02M | $12.98M | $12.09M | $472.59K | $2.35M | $12.39M | $12.13M | $505.44K | $8.57M | $8.07M | $9.20M | $7.73M | $6.23M | $5.89M | $3.08M | $4.26M | $4.21M | $3.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.40% | 1.21% | 26.33% | 1.27% | 0.91% | 0.76% | 0.48% | 0.00% | 1.18% | 1.08% | 1.58% | 0.23% | 0.98% | -0.44% | 0.91% | -0.90% | -1.97% |
3 analysts predict PGNY's average Quarter EBITDA for Mar 24 to be $552.33K, with a high of $662.80K and a low of $441.87K. This is -96.00% lower than Progyny's previous annual EBITDA (Dec 23) of $13.80M.
Progyny Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $13.47M | $15.90M | $14.99M | $17.68M | $3.41M | $13.21M | $8.77M | $4.97M | $15.08M | $16.80M | $18.73M | $15.17M | $38.86M | $5.36M | $-1.81M | $4.06M | $-4.40M | $-8.21M |
| Avg Forecast | $13.14M | $15.95M | $17.83M | $17.83M | $12.51M | $13.54M | $14.07M | $12.73M | $8.63M | $13.42M | $15.89M | $11.73M | $10.08M | $10.76M | $9.64M | $12.55M | $81.11M | $2.94M | $1.22M | $13.42M | $3.52M | $6.09M | $17.28M | $8.87M | $6.30M | $5.03M | $-2.37M | $4.46M | $998.65K | $1.96M |
| High Forecast | $13.45M | $16.33M | $18.25M | $18.25M | $12.81M | $13.86M | $14.41M | $13.04M | $9.37M | $13.74M | $15.91M | $14.08M | $12.32M | $10.77M | $9.88M | $15.06M | $97.33M | $2.94M | $1.22M | $16.11M | $3.52M | $6.09M | $20.73M | $8.87M | $6.30M | $5.03M | $-2.37M | $5.36M | $998.65K | $1.96M |
| Low Forecast | $12.54M | $15.22M | $17.01M | $17.01M | $11.94M | $12.92M | $13.43M | $12.15M | $8.38M | $13.09M | $15.87M | $9.39M | $7.84M | $10.74M | $9.20M | $10.04M | $64.89M | $2.94M | $1.22M | $10.74M | $3.52M | $6.09M | $13.82M | $8.87M | $6.30M | $5.03M | $-2.37M | $3.57M | $998.65K | $1.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.34% | 1.48% | 1.55% | 1.41% | 0.04% | 4.50% | 7.17% | 0.37% | 4.28% | 2.76% | 1.08% | 1.71% | 6.17% | 1.06% | 0.77% | 0.91% | -4.41% | -4.20% |
Progyny's average Quarter net income forecast for Mar 24 is $11.73M, with a range of $9.39M to $14.08M. PGNY's average Quarter net income forecast represents a -12.89% decrease compared to the company's last Quarter net income of $13.47M (Dec 23).
Progyny SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $43.09M | $44.44M | $45.46M | $43.63M | $41.19M | $34.74M | $35.05M | $33.01M | $25.30M | $19.43M | $17.96M | $17.10M | $19.72M | $15.47M | $13.78M | $12.74M | $10.63M | $9.25M |
| Avg Forecast | $51.84M | $53.85M | $54.51M | $51.42M | $48.46M | $49.54M | $50.06M | $47.06M | $46.18M | $49.84M | $51.23M | $77.91M | $46.02M | $45.54M | $43.98M | $83.33M | $41.16M | $32.66M | $31.99M | $89.12M | $22.61M | $21.28M | $16.57M | $20.39M | $16.43M | $15.54M | $8.11M | $14.02M | $11.09M | $10.21M |
| High Forecast | $52.79M | $54.84M | $55.51M | $52.37M | $49.36M | $50.45M | $50.98M | $47.92M | $46.55M | $50.20M | $51.25M | $93.49M | $46.32M | $45.54M | $44.79M | $99.99M | $49.39M | $32.66M | $31.99M | $106.94M | $22.61M | $21.28M | $19.89M | $20.39M | $16.43M | $15.54M | $8.11M | $16.82M | $11.09M | $10.21M |
| Low Forecast | $50.02M | $51.96M | $52.59M | $49.62M | $46.76M | $47.80M | $48.31M | $45.41M | $45.64M | $49.49M | $51.21M | $62.33M | $45.69M | $45.54M | $42.43M | $66.66M | $32.93M | $32.66M | $31.99M | $71.30M | $22.61M | $21.28M | $13.26M | $20.39M | $16.43M | $15.54M | $8.11M | $11.21M | $11.09M | $10.21M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | 0.98% | 1.03% | 0.52% | 1.00% | 1.06% | 1.10% | 0.37% | 1.12% | 0.91% | 1.08% | 0.84% | 1.20% | 1.00% | 1.70% | 0.91% | 0.96% | 0.91% |
Progyny's average Quarter SG&A projection for Mar 24 is $77.91M, based on 3 Wall Street analysts, with a range of $62.33M to $93.49M. The forecast indicates a 80.79% rise compared to PGNY last annual SG&A of $43.09M (Dec 23).
Progyny EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.13 | $0.17 | $0.16 | $0.19 | $0.04 | $0.14 | $0.10 | $0.05 | $0.17 | $0.19 | $0.21 | $0.17 | $0.45 | $0.06 | $-0.02 | $0.05 | $-0.07 | $-0.10 |
| Avg Forecast | $0.14 | $0.17 | $0.19 | $0.19 | $0.13 | $0.14 | $0.15 | $0.14 | $0.09 | $0.14 | $0.17 | $0.13 | $0.11 | $0.11 | $0.10 | $0.07 | $0.01 | $0.03 | $0.01 | $-0.02 | $0.04 | $0.06 | $0.08 | $0.09 | $0.06 | $0.05 | $-0.02 | $0.02 | $0.01 | $0.02 |
| High Forecast | $0.14 | $0.17 | $0.19 | $0.19 | $0.14 | $0.15 | $0.15 | $0.14 | $0.10 | $0.15 | $0.17 | $0.13 | $0.13 | $0.11 | $0.11 | $0.08 | $0.01 | $0.03 | $0.01 | $-0.02 | $0.04 | $0.06 | $0.08 | $0.09 | $0.06 | $0.05 | $-0.02 | $0.02 | $0.01 | $0.02 |
| Low Forecast | $0.13 | $0.16 | $0.18 | $0.18 | $0.13 | $0.14 | $0.14 | $0.13 | $0.09 | $0.14 | $0.17 | $0.13 | $0.08 | $0.11 | $0.10 | $0.07 | $0.01 | $0.03 | $0.01 | $-0.02 | $0.04 | $0.06 | $0.08 | $0.09 | $0.06 | $0.05 | $-0.02 | $0.02 | $0.01 | $0.02 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.21% | 1.48% | 1.56% | 2.56% | 3.43% | 4.67% | 8.00% | -3.00% | 4.72% | 3.05% | 2.52% | 1.88% | 6.99% | 1.17% | 0.83% | 2.07% | -6.86% | -5.00% |
According to 3 Wall Street analysts, Progyny's projected average Quarter EPS for Mar 24 is $0.13, with a low estimate of $0.13 and a high estimate of $0.13. This represents a 1.77% increase compared to PGNY previous annual EPS of $0.13 (Dec 23).
Progyny Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| GDRX | GoodRx | $4.46 | $14.57 | 226.68% | Buy |
| EVH | Evolent Health | $10.87 | $33.00 | 203.59% | Buy |
| TXG | 10x Genomics | $14.72 | $31.75 | 115.69% | Hold |
| SLP | Simulations Plus | $30.04 | $47.00 | 56.46% | Buy |
| PGNY | Progyny | $14.74 | $22.67 | 53.80% | Hold |
| DH | Definitive Healthcare | $4.46 | $6.08 | 36.32% | Hold |
| CERT | Certara | $11.40 | $15.00 | 31.58% | Buy |
| HCAT | Health Catalyst | $7.65 | $9.67 | 26.41% | Buy |
| PHR | Phreesia | $24.86 | $30.75 | 23.69% | Buy |
| PRVA | Privia Health Group | $20.79 | $23.00 | 10.63% | Buy |
| TDOC | Teladoc Health | $10.07 | $11.00 | 9.24% | Buy |
| VEEV | Veeva Systems | $226.41 | $235.50 | 4.01% | Buy |
| HSTM | HealthStream | $31.97 | $29.00 | -9.29% | Buy |